Longeveron Inc. (NASDAQ: LGVN) announced the pricing of a public offering of 5,882,354 Class A common stock shares at $0.85 per share, with short-term warrants for up to 14,705,885 shares. The gross proceeds are expected to be around $5.0 million, with potential additional proceeds of $12.5 million from the warrants. The offering is expected to close on August 11, 2025. The company plans to use the funds for clinical and regulatory development of laromestrocel. Longeveron is a biotech company developing regenerative medicines, focusing on laromestrocel for various disease states.

H.C. Wainwright & Co. is the exclusive placement agent for the offering. The offering is being made through a registration statement on Form S-1. Longeveron’s lead product, laromestrocel, has received important FDA designations for multiple pipeline indications. The company’s forward-looking statements outline various risks and uncertainties related to the offering and product development. For more information, visit Longeveron’s website or contact the Investor Relations Advisory Solutions.

Read more at GlobeNewswire: Longeveron Announces Up To $17.5 Million Public Offering